Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Non-Current Liabilities (2016 - 2025)

Ultragenyx Pharmaceutical has reported Other Non-Current Liabilities over the past 11 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 6647.06% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 6647.06% year-over-year, with the annual reading at $1.1 billion for FY2025, 6647.06% up from the prior year.
  • Other Non-Current Liabilities was $1.1 billion for Q4 2025 at Ultragenyx Pharmaceutical, up from $18.8 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $1.1 billion in Q4 2025 and troughed at $1.0 million in Q4 2021.
  • The 5-year median for Other Non-Current Liabilities is $179.5 million (2021), against an average of $345.6 million.
  • Year-over-year, Other Non-Current Liabilities crashed 99.7% in 2021 and then surged 21529.53% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $1.0 million in 2021, then skyrocketed by 379.6% to $4.8 million in 2022, then skyrocketed by 17790.56% to $862.3 million in 2023, then plummeted by 98.03% to $17.0 million in 2024, then surged by 6647.06% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for RARE's Other Non-Current Liabilities are $1.1 billion (Q4 2025), $18.8 million (Q3 2025), and $17.4 million (Q2 2025).